BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Hsieh MH, Dai CY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Yu ML, Chuang WL. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung J Med Sci 2017;33:394-9. [PMID: 28811008 DOI: 10.1016/j.kjms.2017.05.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Jang TY, Huang CF, Yeh ML, Huang CI, Dai CY, Tsai PC, Hsu PY, Wei YJ, Hou NJ, Liang PC, Lin YH, Wang CW, Hsieh MY, Lin ZY, Huang JF, Yu ML, Chuang WL. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. Kaohsiung J Med Sci 2021. [PMID: 34786828 DOI: 10.1002/kjm2.12474] [Reference Citation Analysis]
2 Cheng Y, Wang C. Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Can Predict Mild or Significant Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115400] [Reference Citation Analysis]
3 Feng S, Wang Z, Zhao Y, Tao C. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Sci Rep 2020;10:10582. [PMID: 32601332 DOI: 10.1038/s41598-020-67471-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Behairy OG, El-Gendy SA, Ibrahim DY, Mansour AI, El-Shimi OS. Mac-2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease. Hepatol Res 2021;51:277-83. [PMID: 33393720 DOI: 10.1111/hepr.13608] [Reference Citation Analysis]
5 Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med 2021;41:16-24. [PMID: 32829576 DOI: 10.3343/alm.2021.41.1.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876 [PMID: 32550761 DOI: 10.3748/wjg.v26.i21.2864] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yeh ML, Huang JF, Yu ML, Chuang WL. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol 2021;15:427-35. [PMID: 33338385 DOI: 10.1080/17474124.2021.1866985] [Reference Citation Analysis]
8 Veyel D, Wenger K, Broermann A, Bretschneider T, Luippold AH, Krawczyk B, Rist W, Simon E. Biomarker discovery for chronic liver diseases by multi-omics - a preclinical case study. Sci Rep 2020;10:1314. [PMID: 31992752 DOI: 10.1038/s41598-020-58030-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]